Skip to main content
MedPathMedPath Home
Clinical Trials/NL-OMON37344
NL-OMON37344
Withdrawn
Phase 2

A randomized double blind placebo controlled study on the effects of fenretinide Lym-X-Sorb on insulin sensitivity in obese insulin resistant subjects - The effects of fenretinide on insulin sensitivity

Academisch Medisch Centrum0 sites20 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsobesitasInsulin resistanceimpaired glucose tolerance1001842410019654

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
obesitas
Sponsor
Academisch Medisch Centrum
Enrollment
20
Status
Withdrawn
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • •Post menopausal female
  • •Age 40\-65 years
  • •BMI \* 30 kg \* m\-2
  • •HOMA\-IR \* 2\.7
  • •Signed informed consent

Exclusion Criteria

  • •T2DM treated with medication other than metformin or sulfonylurea derivates
  • •Any medical condition except for glucose intolerance, T2DM, hypertension and secondary dyslipidemia
  • •Prolonged PTT/aPTT or thrombocytopenia
  • •Retinol levels of \< 1\.8 uM

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Phase 1
SAR231893-LPS15497- Dupilumab effect on Sleep in AD patients”
EUCTR2018-004705-26-ESSanofi Aventis Groupe188
Active, not recruiting
Phase 1
SAR231893-LPS15497- Dupilumab effect on Sleep in AD patients
EUCTR2018-004705-26-ITSANOFI-AVENTIS GROUPE188
Active, not recruiting
Phase 1
SAR231893-LPS15497- Dupilumab effect on Sleep in AD patients”Atopic dermatitisMedDRA version: 20.0Level: PTClassification code 10012438Term: Dermatitis atopicSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersTherapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
EUCTR2018-004705-26-FRSanofi Aventis Groupe268
Active, not recruiting
Phase 1
SAR231893-LPS15497- Dupilumab effect on Sleep in AD patients”
EUCTR2018-004705-26-DESanofi Aventis Groupe268
Active, not recruiting
Phase 1
SAR231893-LPS15497- Dupilumab effect on Sleep in AD patients”Atopic dermatitisMedDRA version: 20.0Level: PTClassification code 10012438Term: Dermatitis atopicSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersTherapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
EUCTR2018-004705-26-GBSanofi Aventis Groupe268